Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting
Autore:
Jauhar, R; Bergman, G; Savino, S; Deutsch, E; Shaknovich, A; Parikh, M; Sanborn, TA;
Indirizzi:
New York Presbyterian Hosp, Dept Med, Div Cardiol, New York, NY 10021 USA New York Presbyterian Hosp New York NY USA 10021 , New York, NY 10021 USA
Titolo Testata:
AMERICAN JOURNAL OF CARDIOLOGY
fascicolo: 6, volume: 84, anno: 1999,
pagine: 726 -
SICI:
0002-9149(19990915)84:6<726:EOAACC>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
ANTIPLATELET THERAPY; COMBINED TICLOPIDINE; IMPLANTATION; MULTICENTER; ANTICOAGULATION; TRIAL; RISK;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
18
Recensione:
Indirizzi per estratti:
Indirizzo: Jauhar, R New York Presbyterian Hosp, Dept Med, Div Cardiol, 525 E 68th St,Cornell Campus, New York, NY 10021 USA New York Presbyterian Hosp 525 E 68th St,Cornell Campus New York NY USA 10021
Citazione:
R. Jauhar et al., "Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting", AM J CARD, 84(6), 1999, pp. 726

Abstract

Intracoronary stents have significantly advanced the treatment of coronaryartery disease.(1-3) Early data with self-expanding stents, however, showed early stent thrombosis rates of 24%.(4) Aggressive antiplatelet and anticoagulation regimens of dextran, aspirin, dipyridamole, and warfarin led to a reduction in early stent thrombosis to 3% to 4%, but greatly increased the rate of bleeding and vascular complications to as high as 13%.(2) Combination antiplatelet therapy after intracoronary stenting with aspirin and ticlopidine became standard practice after several nonrandomized trials showedreduced complication rates in patients with stents.(5-7) More recently, randomized trials demonstrated that aspirin and ticlopidine had a significantly lower primary cardiac end point rate (0.5%) than aspirin alone (3.6%) orthan aspirin and warfarin (2.7%) in patients with coronary stents.(8-10) Ticlopidine, however, carries the risk of severe neutropenia (0.8% of patients), and compliance may be limited by twice-a-day dosing and,gastrointestinal intolerance. Recently, a new thienopyridine in the same class as ticlopidine, clopidogrel (Plavix, Bristol-Myers-Squibb, Princeton, New Jersey), has been introduced which has the purported advantage of a reduced incidence of severe neutropenia (0.04%), once-a-day dosing, a better side-effect profile, and a more rapid onset of action.(11) This study evaluates the safety,in-hospital, and 30-day clinical outcome in patients treated with aspirin and a 2-week course of clopidogrel after coronary stenting.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 08:02:48